India markets close in 1 hour 10 minutes
  • BSE SENSEX

    47,929.33
    -151.34 (-0.31%)
     
  • Nifty 50

    14,353.25
    -52.90 (-0.37%)
     
  • USD/INR

    74.9900
    -0.1200 (-0.16%)
     
  • Dow

    33,815.90
    -321.41 (-0.94%)
     
  • Nasdaq

    13,818.41
    -131.81 (-0.94%)
     
  • BTC-INR

    3,627,261.00
    -440,869.00 (-10.84%)
     
  • CMC Crypto 200

    1,098.58
    -144.48 (-11.62%)
     
  • Hang Seng

    29,078.75
    +323.41 (+1.12%)
     
  • Nikkei

    29,020.63
    -167.54 (-0.57%)
     
  • EUR/INR

    90.4177
    +0.1431 (+0.16%)
     
  • GBP/INR

    104.0531
    +0.1163 (+0.11%)
     
  • AED/INR

    20.3540
    -0.0510 (-0.25%)
     
  • INR/JPY

    1.4366
    +0.0020 (+0.14%)
     
  • SGD/INR

    56.4780
    -0.0540 (-0.10%)
     

Xencor to Present at the Barclays Global Healthcare Conference

·1-min read

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 2:25 p.m. ET / 11:25 p.m. PT.

A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005914/en/

Contacts

Charles Liles
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com